[go: up one dir, main page]

BRPI0508574A - métodos para modular receptores de glutamato para tratar distúrbios neuropsiquiátricos compreendendo o uso de moduladores de quinases séricas e induzidas por glicocorticóides - Google Patents

métodos para modular receptores de glutamato para tratar distúrbios neuropsiquiátricos compreendendo o uso de moduladores de quinases séricas e induzidas por glicocorticóides

Info

Publication number
BRPI0508574A
BRPI0508574A BRPI0508574-8A BRPI0508574A BRPI0508574A BR PI0508574 A BRPI0508574 A BR PI0508574A BR PI0508574 A BRPI0508574 A BR PI0508574A BR PI0508574 A BRPI0508574 A BR PI0508574A
Authority
BR
Brazil
Prior art keywords
methods
serum
glutamate receptors
glucocorticoid
neuropsychiatric disorders
Prior art date
Application number
BRPI0508574-8A
Other languages
English (en)
Inventor
Florian Lang
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI0508574A publication Critical patent/BRPI0508574A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)

Abstract

MéTODOS PARA MODULAR RECEPTORES DE GLUTAMATO PARA TRATAR DISTúRBIOS NEUROPSIQUIáTRICOS COMPREENDENDO O USO DE MODULADORES DE QUINASES SéRICAS E INDUZIDAS POR GLICOCORTICóIDES.A presente invenção refere-se a modulação da atividade de quinases séricas e induzidas por glicocorticóide para restaurar a atividade do receptor de glutamanto.Também descritos são métodos e compostos úteis para a detecção e tratamento de distúrbios
BRPI0508574-8A 2004-03-11 2005-02-08 métodos para modular receptores de glutamato para tratar distúrbios neuropsiquiátricos compreendendo o uso de moduladores de quinases séricas e induzidas por glicocorticóides BRPI0508574A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04005761 2004-03-11
PCT/EP2005/001245 WO2005094829A1 (en) 2004-03-11 2005-02-08 Methods for modulating glutamate receptors for treating neuropsychiatric disorders comprising the use of modulators of serum and glucocorticoid inducible kinases

Publications (1)

Publication Number Publication Date
BRPI0508574A true BRPI0508574A (pt) 2007-08-14

Family

ID=34960898

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508574-8A BRPI0508574A (pt) 2004-03-11 2005-02-08 métodos para modular receptores de glutamato para tratar distúrbios neuropsiquiátricos compreendendo o uso de moduladores de quinases séricas e induzidas por glicocorticóides

Country Status (12)

Country Link
US (1) US20070191326A1 (pt)
EP (1) EP1732563A1 (pt)
JP (1) JP2007529423A (pt)
KR (1) KR20070015148A (pt)
CN (1) CN1929846A (pt)
AU (1) AU2005229496A1 (pt)
BR (1) BRPI0508574A (pt)
CA (1) CA2559136A1 (pt)
MX (1) MXPA06010268A (pt)
RU (1) RU2006135654A (pt)
WO (1) WO2005094829A1 (pt)
ZA (1) ZA200608447B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007087985A1 (en) * 2006-01-31 2007-08-09 Merck Patent Gmbh Methods for interfering with glucocorticoid induced gastric acid secretion
CA2643559A1 (en) 2006-03-02 2007-09-07 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
US20070259875A1 (en) * 2006-04-28 2007-11-08 Atwal Karnail S Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof
AU2009279756B2 (en) 2008-08-05 2015-01-29 Omeros Corporation PDE10 inhibitors and related compositions and methods
WO2011014775A1 (en) 2009-07-31 2011-02-03 The Brigham And Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
RU2580654C1 (ru) * 2015-04-16 2016-04-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздрава России) Способ лечения эпилепсий с продолженной спайк-волновой активностью во сне
EP3585371B1 (en) 2017-02-24 2024-07-10 Indiana University Research and Technology Corporation Methods of inhibiting serum glucocorticoid induced kinase 1 (sgk1) as a treatment for salt and water balance diseases
KR102331240B1 (ko) * 2019-03-21 2021-11-29 재단법인대구경북과학기술원 Sgk3 유전자를 이용한 뇌신경계 질환의 진단 및 치료
KR20210008193A (ko) * 2019-07-10 2021-01-21 한양대학교 산학협력단 염증성 신경 질환의 치료제로서 Sgk1 저해제의 용도
KR102645546B1 (ko) * 2021-06-10 2024-03-08 전남대학교 산학협력단 간성뇌증에 의해 유발되는 신경학적 또는 정신학적 장애 관련 질환 진단용 마커 및 이를 이용한 간성뇌증에 의해 유발되는 신경학적 또는 정신학적 장애 관련 질환 진단에 필요한 정보를 제공하는 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19708173A1 (de) * 1997-02-28 1998-09-03 Dade Behring Marburg Gmbh Zellvolumenregulierte humane Kinase h-sgk
EP0889127A1 (en) * 1997-07-01 1999-01-07 Smithkline Beecham Corporation Serine/threonine protein kinase (H-SGK2)
JPH11106371A (ja) * 1997-07-04 1999-04-20 Nisshin Flour Milling Co Ltd アシルヒドラゾン誘導体
DE69937159T2 (de) * 1998-12-14 2008-06-26 University Of Dundee, Dundee Verfahren zur Aktivierung von SGK durch Phosphorylierung.
DE19917990A1 (de) * 1999-04-20 2000-11-02 Florian Lang Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk
US20050064501A1 (en) * 1999-04-20 2005-03-24 Prof. Dr. Med. F. Lang Medicaments comprising inhibitors of the cell volume-regulated human kinase h-sgk
DE10042137A1 (de) * 2000-08-28 2002-03-14 Florian Lang sgk2 und sgk3 als diagnostische und therapeutische Targets
DE10305212A1 (de) * 2003-02-07 2004-08-19 Florian Prof. Dr.med. Lang Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom
DE10346913A1 (de) * 2003-10-09 2005-05-04 Merck Patent Gmbh Acylhydrazonderivate
DE10352979A1 (de) * 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone

Also Published As

Publication number Publication date
CA2559136A1 (en) 2005-10-13
WO2005094829A1 (en) 2005-10-13
KR20070015148A (ko) 2007-02-01
RU2006135654A (ru) 2008-09-10
MXPA06010268A (es) 2007-04-23
EP1732563A1 (en) 2006-12-20
AU2005229496A1 (en) 2005-10-13
CN1929846A (zh) 2007-03-14
JP2007529423A (ja) 2007-10-25
ZA200608447B (en) 2008-07-30
US20070191326A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
BRPI0511072A (pt) derivados de alquinila como moduladores dos receptores de glutamato metabotróbico
BRPI0511616A (pt) compostos
ATE469151T1 (de) Pyrrolopyridinderivate als proteinkinaseinhibitoren
BRPI0513916A (pt) moduladores de pirrol-piridina cinase
CY1120922T1 (el) Παραγωγα πυρρολιου ως φαρμακευτικοι παραγοντες
BRPI0509207A (pt) moduladores canabinóides de tetraidro-indazol
UA98297C2 (en) Triazolopyridazines as tyrosine kinase modulators
BRPI0920261A8 (pt) Composto, composição farmacêutica, uso do composto, e, método para inibir ou modular atividade de proteína quinase em uma amostra biológica
EA200870048A1 (ru) ГЕТЕРОАРИЛ-ЗЕМЕЩЕННЫЕ ПИРРОЛО[2,3-b]ПИРИДИНЫ И ПИРРОЛО[2,3-b]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
BRPI0510095A (pt) tiazol substituìdo e derivados de pirimidina como moduladores de receptores de melanocortina
EA200971077A1 (ru) Гетероциклические модуляторы киназы
CY1110828T1 (el) Τροποποιημενοι πυριμιδινικοι ρυθμιστες του γλυκοκορτικοειδους υποδοχεα
EA200970402A1 (ru) Триазолопиридазиновые модуляторы протеинкиназ
DE60336901D1 (de) Chinazolinon modulatoren von nukleinrezeptoren
BRPI0508574A (pt) métodos para modular receptores de glutamato para tratar distúrbios neuropsiquiátricos compreendendo o uso de moduladores de quinases séricas e induzidas por glicocorticóides
CR7056A (es) Derivados de 3-(4-amidopirrol-2-ilmetilden)-2-indolinona como inhibidores de la protein quinasa
ECSP077991A (es) Aminopirimidinas como moduladores de cinasa
ECSP077998A (es) Moduladores de cinasa de aminoquinolina y aminoquinazolina
EA200901646A1 (ru) Ингибиторы рецепторных тирозинкиназ и их применение
CL2007002595A1 (es) Compuestos derivados de n-(1-hetaril-piperidin-4-il)-(het)arilamida, moduladores del receptor ep2; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de la fertilidad, trastornos menstruale
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
IL190348A0 (en) Hexahydro cyclooctyl pyrazole cannabinoid modulators
SV2009003212A (es) Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct
BR0313624A (pt) Agonismo do receptor 5ht2a para tratamento da disfunção termo-regulatória
BRPI0507645A (pt) anticorpo, método de detectar um distúrbio ósseo metabólico, kit para detectar um distúrbio ósseo metabólico, composição farmacêutica para o tratamento de um distúrbio ósseo metabólico, e, método de triar uma substáncia efetiva para tratar e/ou prevenir um distúrbio ósseo metabólico

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.